Morgan Stanley reiterated its Overweight rating on Pfizer PFE. At the same time, the rating agency decided to leave its price target on the company's stock unchanged at $22. On Thursday, Pfizer ended the day at $20.65. Its shares lost 0.44% in today's pre-market trading to trade around $20.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in